New hope for rare bleeding disorder: emicizumab trial launches

NCT ID NCT05345197

Ongoing Disease control Sponsor: University of Washington Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 trial tests the drug emicizumab (Hemlibra) as a regular injection to prevent bleeding in 51 adults with acquired hemophilia A, a rare condition where the immune system attacks clotting factors. Participants receive two loading doses then weekly shots, along with standard immune-suppressing therapy. The main goal is to see how many serious bleeds occur over 12 weeks.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: emicizumab (Hemlibra)
What this could lead to: If successful, this could provide a new way to prevent dangerous bleeding episodes in people with acquired hemophilia A, reducing the need for frequent hospital visits.
What could go wrong: This is a small, early-phase trial with no comparison group. Risks include blood clots or other side effects, and the treatment may not work for everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acquired hemophilia A

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACQUIRED HEMOPHILIA A

Contacts and locations

Show contact details

Locations

Bleeding and Clotting Disorders Institute

Peoria, Illinois, 61614, United States
Emory University

Atlanta, Georgia, 30308, United States
Georgetown University

Washington D.C., District of Columbia, 20007, United States
Hemophilia Center of Western Pennsylvania

Pittsburgh, Pennsylvania, 15213, United States
Indiana Hemophilia and Thrombosis Center, Inc.

Indianapolis, Indiana, 46260, United States
Mayo Clinic

Rochester, Minnesota, 55905, United States
Penn Blood Disorders Program, Hospital of the University of Pennsylvania

Philadelphia, Pennsylvania, 19104, United States
Tulane University

New Orleans, Louisiana, 70112-2632, United States
UCSD Hemophilia and Thrombosis Treatment Center

San Diego, California, 92121, United States
UVA Comprehensive Cancer Center

Charlottesville, Virginia, 22908, United States
University of North Carolina

Chapel Hill, North Carolina, 27514, United States
University of Oklahoma Health Sciences Center

Oklahoma City, Oklahoma, 73104, United States
University of Vermont Medical Center

Burlington, Vermont, 05401, United States
Versiti Inc.

Milwaukee, Wisconsin, 53226, United States
Washington Center for Bleeding Disorders

Seattle, Washington, 98101, United States
Washington University

St Louis, Missouri, 63110, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.